Akums Drugs & Pharmaceuticals Ltd
AKUMS NSE
Akums Drugs & Pharmaceuticals Ltd
HealthcareNSE: AKUMS BSE: 544222 Pharmaceuticals & Biotechnology
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹9,727 Cr
Volatility
Moderate
P/E Ratio
37.59
EBITDA
₹651 Cr
Return on Equity
0.11%
Debt to Equity
0.04
Book Value
₹210.57
EPS
₹0
52W High
₹639
52W Low
₹409.3
Technical Indicators
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Stock is trading at 2.91 times its book value
- The company has delivered a poor sales growth of 9.87% over past five years.
- Company has a low return on equity of 9.72% over last 3 years.
Growth Rate
Revenue Growth
7.51% ↗
Net Income Growth
-25.42% ↘
Cash Flow Change
153.91% ↗
ROE
-31.37% ↘
ROCE
-7.29% ↘
EBITDA Margin (Avg.)
17.12% ↗
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 |
| OPM % | -13% | 13% | 9% | 0% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 |
| PBT | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,464 | 1,651 | 2,414 | 2,723 | 3,672 | 3,655 | 4,178 | 4,118 | 4,359 |
| Expenses | 1,340 | 1,507 | 2,240 | 2,485 | 3,761 | 3,361 | 4,055 | 3,657 | 3,837 |
| Operating Profit | 124 | 144 | 174 | 238 | -89 | 294 | 123 | 461 | 522 |
| OPM % | 8% | 9% | 7% | 9% | -2% | 8% | 3% | 11% | 12% |
| Other Income | 6 | 6 | 26 | 11 | 7 | 15 | 8 | 73 | 108 |
| Interest | 23 | 22 | 20 | 7 | 17 | 46 | 51 | 35 | 94 |
| Depreciation | 31 | 38 | 67 | 70 | 95 | 113 | 126 | 153 | 155 |
| PBT | 77 | 89 | 114 | 172 | -193 | 150 | -45 | 345 | 382 |
| Tax % | 51% | 50% | 62% | 28% | 30% | 35% | -102% | 0% | 33% |
| Net Profit | 43 | 61 | 44 | 123 | -251 | 98 | 1 | 344 | 256 |
| EPS in Rs | 367 | 523 | 336 | 943 | -35.3 | 6.63 | -0.28 | 21.49 | 16.21 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 18% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 1 | 14 | 29 | 29 | 31 | 31 |
| Reserves | 493 | 628 | 721 | 884 | 608 | 689 | 681 | 3,016 | 3,283 |
| Borrowings | 255 | 213 | 175 | 130 | 395 | 619 | 565 | 88 | 157 |
| Other Liabilities | 293 | 318 | 1,140 | 1,137 | 2,033 | 1,905 | 2,229 | 960 | 1,958 |
| Total Liabilities | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
| Fixed Assets | 444 | 501 | 645 | 904 | 1,021 | 1,097 | 1,191 | 1,397 | 1,456 |
| CWIP | 0 | 11 | 57 | 17 | 31 | 103 | 195 | 163 | 177 |
| Investments | 0 | 18 | 6 | 20 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 598 | 632 | 1,329 | 1,212 | 1,998 | 2,041 | 2,118 | 2,535 | 3,796 |
| Total Assets | 1,042 | 1,161 | 2,037 | 2,152 | 3,050 | 3,241 | 3,504 | 4,095 | 5,429 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 72 | 89 | 28 | 131 | 32 | 177 | 498 | 465 | 1,181 |
| Investing | -150 | -123 | -190 | -109 | -235 | -305 | -331 | -548 | -930 |
| Financing | 66 | 37 | 233 | -91 | 236 | 125 | -108 | 73 | 34 |
| Net Cash Flow | -11 | 4 | 71 | -70 | 33 | -4 | 59 | -10 | 285 |
| Free Cash Flow | -78 | -34 | -34 | 49 | -224 | -110 | 212 | 201 | 958 |
| CFO/OP | 72 | 98 | 44 | 74 | -98 | 93 | 455 | 119 | 243 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 57 | 88 | 71 | 88 | 84 | 73 | 68 | 67 |
| Inventory Days | 114 | 115 | 99 | 93 | 112 | 117 | 90 | 102 | 110 |
| Days Payable | 67 | 60 | 105 | 74 | 92 | 91 | 76 | 96 | 87 |
| Cash Conversion Cycle | 115 | 112 | 82 | 90 | 109 | 111 | 87 | 74 | 89 |
| Working Capital Days | 78 | 73 | 55 | 66 | 49 | 46 | 40 | 71 | 66 |
| ROCE % | — | 14% | — | 20% | -16% | 22% | 2% | 16% | 15% |
Documents
1
Board Meeting Intimation for Board Meeting Intimation
4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend. 4h - Board meets May 14, 2026 to approve FY26 audited results and consider dividend.
2
ESG Rating
8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026. 8 May - Akums received unsolicited ESG rating of 63 for FY2024-25 from NSE Sustainability on 7 May 2026.
3
Execution Of Lease Deed
29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.
4
Execution Of Lease Deed
29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026. 29 Apr - Pure and Cure Healthcare leased 4,050 sq. m industrial plot at Haridwar on April 28, 2026.
5
Announcement under Regulation 30 (LODR)-Credit Rating
11 Apr - ICRA reaffirmed AA (Stable)/A1+ for working capital limits and assigned A1+ to ₹200 crore CP programme. 11 Apr - ICRA reaffirmed AA (Stable)/A1+ for working capital limits and assigned A1+ to ₹200 crore CP programme.
Frequently Asked Questions about Akums Drugs & Pharmaceuticals Ltd
What does Akums Drugs & Pharmaceuticals Ltd do?
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Where is Akums Drugs & Pharmaceuticals Ltd (AKUMS) listed?
Akums Drugs & Pharmaceuticals Ltd is listed on the Indian stock exchanges. It is listed on NSE: AKUMS and BSE: 544222. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Akums Drugs & Pharmaceuticals Ltd belong to?
Akums Drugs & Pharmaceuticals Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a market capitalisation of approximately ₹9726.95 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Akums Drugs & Pharmaceuticals Ltd?
The Price-to-Earnings (PE) ratio of Akums Drugs & Pharmaceuticals Ltd is 37.59. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd?
Over the past 52 weeks, Akums Drugs & Pharmaceuticals Ltd has traded between a low of ₹409.3 and a high of ₹639. This range helps investors understand the stock's price volatility and recent trading levels.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Yes, Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.49%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a Return on Equity (ROE) of 0.11%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Akums Drugs & Pharmaceuticals Ltd on Tapetide?
On Tapetide, you can view Akums Drugs & Pharmaceuticals Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Website akums.in
CEO Mr. Sanjeev Jain
Employees 7,536
Listed 2024-08-06
Face Value ₹ 2
Issued Size 15,73,93,988